REFERENCES
1. Sahu I, Zhu H, Buhrlage SJ, Marto JA. Proteomic approaches to study ubiquitinomics. Biochim Biophys Acta Gene Regul Mech. 2023;1866:194940.
3. Song L, Luo ZQ. Post-translational regulation of ubiquitin signaling. J Cell Biol. 2019;218:1776-86.
4. Faccenda E, Layfield R. E3 ubiquitin ligase components in GtoPdb v.2022.3. IUPHAR BPS Guide Pharmacol CITE. 2022.
5. Snyder NA, Silva GM. Deubiquitinating enzymes (DUBs): regulation, homeostasis, and oxidative stress response. J Biol Chem. 2021;297:101077.
6. Liu C, Yuan Y, Zhan Y, et al. Role of the USP family in autophagy regulation and cancer progression. Apoptosis. 2025;30:1133-51.
7. Pan X, Wu S, Wei W, Chen Z, Wu Y, Gong K. Structural and functional basis of JAMM deubiquitinating enzymes in disease. Biomolecules. 2022;12:910.
8. Tang X, Li Y, Liu Y. Dissecting the dual role of OTU family proteins in tumor progression and immune escape. Front Immunol. 2025;16:1544341.
9. Bustamante HA, Albornoz N, Morselli E, Soza A, Burgos PV. Novel insights into the non-canonical roles of PSMD14/POH1/Rpn11 in proteostasis and in the modulation of cancer progression. Cell Signal. 2023;101:110490.
10. Liang XY, Zhang Y, He YN, et al. A cancer stem cell associated gene signature for predicting overall survival of hepatocellular carcinoma. Front Genet. 2022;13:888601.
11. Gong Y, Wei ZR. Identification of PSMD14 as a potential novel prognosis biomarker and therapeutic target for osteosarcoma. Cancer Rep. 2022;5:e1522.
12. Schnoell J, Scheiflinger A, Al-Gboore S, et al. The prognostic role of PSMD14 in head and neck squamous cell carcinoma. J Cancer Res Clin Oncol. 2023;149:2483-90.
13. Teng X, Yang T, Yuan B, et al. Prognostic analysis of patients with breast cancer based on tumor mutational burden and DNA damage repair genes. Front Oncol. 2023;13:1177133.
14. Lu T, Xu R, Wang C, et al. Bioinformatics analysis and single-cell RNA sequencing: elucidating the ubiquitination pathways and key enzymes in lung adenocarcinoma. J Thorac Dis. 2023;15:3885-907.
15. Shi Y, Tang Q, Sheng S, et al. PSMD14 stabilizes SLC7A11 to ameliorate glucocorticoid-induced osteoporosis by suppressing osteocyte ferroptosis. Adv Sci. 2025;12:e14902.
16. Zhang Q, Zhang C, Liu C, et al. Identification and validation of novel potential pathogenesis and biomarkers to predict the neurological outcome after cardiac arrest. Brain Sci. 2022;12:928.
17. Xue R, Dong YC, Wang X, Liang SZ, Fan XL, Wan GM. Ethyl ferulate suppresses choroidal neovascularization by accelerating Keap1 degradation through the inhibition of PSMD14-mediated deubiquitination. Phytomedicine. 2026;153:157913.
18. Yang P, Yang X, Wang D, et al. PSMD14 stabilizes estrogen signaling and facilitates breast cancer progression via deubiquitinating ERα. Oncogene. 2024;43:248-64.
19. Wang Y, Liu Y, Ma C, et al. Deubiquitinase PSMD14 promotes tumorigenicity of glioblastoma by deubiquitinating and stabilizing β-catenin. Biofactors. 2024;50:1134-47.
20. Wang Y, Duan Y, Yue K, et al. Blocking PSMD14-mediated E2F1/ERK/AKT signaling pathways suppresses the progression of anaplastic thyroid cancer. Cell Signal. 2025;132:111826.
21. Lu J, Wu H, Zhan P, et al. PSMD14-mediated deubiquitination of CARM1 facilitates the proliferation and metastasis of hepatocellular carcinoma by inducing the transcriptional activation of FERMT1. Cell Death Dis. 2025;16:141.
22. Xie J, Zhao S, Wu D, et al. A metabolism-driven prognostic model and PSMD14-SP1-GYS1 axis reveal therapeutic vulnerabilities in melanoma. J Invest Dermatol. 2026;146:1074-88.e5.
23. Zeng XY, Nie Y, Zhu CY, et al. DUSP4-mediated dephosphorylation of PSMD14 enhances PSMD14-dependent deubiquitination of MICALL2 and promotes malignant progression in clear cell renal cell carcinoma. J Transl Med. 2026;24:790.
24. Jia C, Zhang X, Qu T, et al. Depletion of PSMD14 suppresses bladder cancer proliferation by regulating GPX4. PeerJ. 2023;11:e14654.
25. Zhou M, Li X, Wang W, Wu J, Tan J. PSMD14/E2F1 axis-mediated CENPF promotes the metastasis of triple-negative breast cancer through inhibiting ferroptosis. Cancer Sci. 2025;116:2281-95.
26. Yu Y, Hu J, Wang W, et al. Targeting PSMD14 combined with arachidonic acid induces synthetic lethality via FADS1 m6A modification in triple-negative breast cancer. Sci Adv. 2025;11:eadr3173.
27. Cai D, Zhong GC, Zhao Z, et al. L-lactate-driven PSMD14 lactylation and stabilization promote lactate production and ferroptosis resistance via ENO1 in intrahepatic cholangiocarcinoma. Cancer Lett. 2026;646:218394.
28. Lee HJ, Lee DM, Seo MJ, Kang HC, Kwon SK, Choi KS. PSMD14 targeting triggers paraptosis in breast cancer cells by inducing proteasome inhibition and Ca2+ imbalance. Int J Mol Sci. 2022;23:2648.
29. Zhu R, Liu Y, Zhou H, et al. Deubiquitinating enzyme PSMD14 promotes tumor metastasis through stabilizing SNAIL in human esophageal squamous cell carcinoma. Cancer Lett. 2018;418:125-34.
30. Yuan Y, Li Y, Wu X, et al. POH1 induces Smad3 deubiquitination and promotes lung cancer metastasis. Cancer Lett. 2024;582:216526.
31. Sun T, Liu Z, Bi F, Yang Q. Deubiquitinase PSMD14 promotes ovarian cancer progression by decreasing enzymatic activity of PKM2. Mol Oncol. 2021;15:3639-58.
32. Liu Y, Wen S, Wang W, et al. PSMD14 promotes breast cancer progression by reducing K63-linked ubiquitination on FOXM1 and activating the PI3K/AKT/mTOR pathway. Int J Biol Macromol. 2025;327:147275.
33. Zhao Z, Xu H, Wei Y, Sun L, Song Y. Deubiquitylase PSMD14 inhibits autophagy to promote ovarian cancer progression via stabilization of LRPPRC. Biochim Biophys Acta Mol Basis Dis. 2023;1869:166594.
34. Li D, Wang M. An LRPPRC-HAPSTR1-PSMD14 interaction regulates tumor progression in ovarian cancer. Aging. 2024;16:6773-95.
35. Song W, Li Z, Xia M, Xiao W. Regulation of Drp1 and enhancement of mitochondrial fission by the deubiquitinating enzyme PSMD14 facilitates the proliferation of bladder cancer cells. Oncol Rep. 2024;51:6.
36. Jing T, Xu X, Wu C, et al. POH1 facilitates pancreatic carcinogenesis through MYC-driven acinar-to-ductal metaplasia and is a potential therapeutic target. Cancer Lett. 2023;577:216444.
37. Lu RS, Ren LK, Fei XB, et al. PSMD14-mediated LDHA deubiquitination upregulates ACLY expression via H3K18 lactylation to promote lipid synthesis and pancreatic cancer progression. Adv Sci. 2025;12:e05762.
38. Zhao X, Li M, Fu Y, et al. PSMD14-mediated PFKFB2 deubiquitination activates H3K27 lactylation to drive cancer stemness in gastric adenocarcinoma. Cell Death Differ. 2026;33:813-30.
39. Xiao H, Wang B, Xiong HX, et al. A novel prognostic index of hepatocellular carcinoma based on immunogenomic landscape analysis. J Cell Physiol. 2021;236:2572-91.
40. Zhang J, Sun B, Lai J, et al. Expression of PSMD14 in lung adenocarcinoma and its impact on immune cell infiltration and prognosis: a comprehensive analysis based on RNA and single-cell RNA sequencing. Front Immunol. 2025;16:1560693.
41. Wen S, Liu Y, Liu Q, et al. Targeting PSMD14 enhances immunotherapy efficacy by promoting PD-L1 degradation and reshaping the tumor microenvironment in breast cancer. J Exp Clin Cancer Res. 2026;45:124.
42. Yu S, Wang M, Jiang C, et al. Targeting the PSMD14-BCKDK pathway overcomes immune suppression and enhances CAR-NK infiltration in glioblastoma. Cell Death Differ. 2026.
43. Jing C, Duan Y, Zhou M, et al. Blockade of deubiquitinating enzyme PSMD14 overcomes chemoresistance in head and neck squamous cell carcinoma by antagonizing E2F1/Akt/SOX2-mediated stemness. Theranostics. 2021;11:2655-69.
44. Seo D, Jung SM, Park JS, et al. The deubiquitinating enzyme PSMD14 facilitates tumor growth and chemoresistance through stabilizing the ALK2 receptor in the initiation of BMP6 signaling pathway. EBioMedicine. 2019;49:55-71.
45. Wang J, Cao Q, Li Z, et al. Coupling proteostasis and de novo purine biosynthesis of PSMD14 fuels glioblastoma progression and chemoresistance. Theranostics. 2026;16:3599-615.
46. Liu Z, Wang X, Li C, Zhao R. The function and mechanism of PSMD14 in promoting progression and resistance to anlotinib in osteosarcoma. Cancer Cell Int. 2023;23:309.
47. Song Y, Li S, Ray A, et al. Blockade of deubiquitylating enzyme Rpn11 triggers apoptosis in multiple myeloma cells and overcomes bortezomib resistance. Oncogene. 2017;36:5631-8.
48. He L, Yu C, Qin S, et al. The proteasome component PSMD14 drives myelomagenesis through a histone deubiquitinase activity. Mol Cell. 2023;83:4000-16.e6.
49. Dong SY, Ding S, Meng Z, Zou B. The clinicopathological and prognostic significance of PSMD14 in cancers based on bioinformatics and meta-analysis. Future Sci OA. 2024;10:2409054.
50. Yang YH, Xing ZH, Wang H, et al. PSMD11 and PSMD14 may serve as novel biomarkers for the prognosis of pancreatic ductal adenocarcinoma. Front Oncol. 2025;15:1555649.
51. Lei J, Liu X, Liu W, Zhang Y, Liu Z. The prognostic value of USP14 and PSMD14 expression in non-small cell lung cancer. Ann Transl Med. 2021;9:1019.
52. Wang H, Yong X, Gao Y, et al. Integrative analysis of bulk and single-nucleus transcriptomes suggests proteostasis- and metabolism-related alterations in the right ventricular outflow tract of non-syndromic Tetralogy of Fallot. Funct Integr Genomics. 2026;26:121.
53. Cai Q, Duan J, Ding L. Prognostic model of immune-related genes for patients with hepatocellular carcinoma. Front Surg. 2022;9:819491.
54. Wang Y, Feng Z, Zhang Y, Zhang Y. Establishment and verification of a prognostic risk score model based on immune genes for hepatocellular carcinoma in an Asian population. Transl Cancer Res. 2023;12:2806-22.
55. Gao F, Wang Z, Gu J, Zhang X, Wang H. A hypoxia-associated prognostic gene signature risk model and prognosis predictors in gliomas. Front Oncol. 2021;11:726794.
56. Yan Z, Yu J, Wang S, Wen W, Xin M, Li X. Identification of E3 ubiquitin ligase-associated prognostic genes and construction of a prediction model for uterine cervical cancer based on bioinformatics analysis. Discov Oncol. 2024;15:395.
57. Li W, Shan C, Liang L, Zheng G, Zhang S. Polyamine metabolism and immune related genes as prognostic features in breast cancer: a novel risk model approach. Transl Cancer Res. 2025;14:3714-29.
58. Chen L, Wang S, Wang J, Xu B, Tan J, Xia X. Machine learning unveils hypoxia-immune gene hub for clinical stratification of thyroid-associated ophthalmopathy. Sci Rep. 2025;15:22021.
59. Xiong YM, Zhou F, Zhou JW, et al. Aberrant expressions of PSMD14 in tumor tissue are the potential prognostic biomarkers for hepatocellular carcinoma after curative resection. Curr Genomics. 2023;24:368-84.
60. Lauinger L, Li J, Shostak A, et al. Thiolutin is a zinc chelator that inhibits the Rpn11 and other JAMM metalloproteases. Nat Chem Biol. 2017;13:709-14.
61. Jing C, Li X, Zhou M, et al. The PSMD14 inhibitor Thiolutin as a novel therapeutic approach for esophageal squamous cell carcinoma through facilitating SNAIL degradation. Theranostics. 2021;11:5847-62.
62. He G, Wu Z, Yang X, et al. Design and synthesis of thiolutin derived PSMD14/HDAC dual-target inhibitors against esophageal squamous cell carcinoma. Bioorg Chem. 2025;161:108500.
63. Perez C, Li J, Parlati F, et al. Discovery of an inhibitor of the proteasome subunit Rpn11. J Med Chem. 2017;60:1343-61.
64. Li J, Yakushi T, Parlati F, et al. Capzimin is a potent and specific inhibitor of proteasome isopeptidase Rpn11. Nat Chem Biol. 2017;13:486-93.
65. Chen R, Wang S, Xie J. PSMD14 drives lung adenocarcinoma progression through HMMR stabilization and dual activation of TGF-β/Smad and PI3K/AKT/mTOR signaling. Front Immunol. 2025;16:1720799.
66. Yu W, Li J, Wang Q, et al. Targeting POH1 inhibits prostate cancer cell growth and enhances the suppressive efficacy of androgen deprivation and docetaxel. Prostate. 2019;79:1304-15.
67. Zheng Y, Tao Y, Tan F, et al. Acid-responsive cobalt-doped ZIF-8 nanoplatform potentiates ferroptosis in osteosarcoma by disrupting the PSMD14/SLC7A11 axis. Biomater Adv. 2026;188:215008.
68. Li J, Zhang Y, Da Silva Sil Dos Santos B, et al. Epidithiodiketopiperazines inhibit protein degradation by targeting proteasome deubiquitinase Rpn11. Cell Chem Biol. 2018;25:1350-8.e9.
